TECH - Bio-Techne Corporation

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

Bio-Techne Corporation

614 McKinley Place NE
Minneapolis, MN 55413
United States
612-379-8854
http://www.bio-techne.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees2,100

Key Executives

NameTitlePayExercisedYear Born
Mr. Charles R. KummethCEO, Pres & Director2.56MN/A1960
Mr. James T. HippelSr. VP of Fin. & CFO968.88kN/A1971
Ms. Brenda S. FurlowGen. Counsel, Sec. & Chief Compliance Officer643.23kN/A1958
Mr. N. David EansorPres of Protein Sciences Segment866.28kN/A1961
Mr. Gerry AndrosVP of Sales and MarketingN/AN/AN/A
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells biotechnology reagents, instruments, and clinical diagnostic controls worldwide. It operates in three segments: Biotechnology, Protein Platforms, and Diagnostics. The Biotechnology segment offers specialized proteins, such as cytokines and growth factors, immunoassays, antibodies, and related reagents to the biotechnology research community; and in situ hybridization, media, and other cell culture products and reagents. It also provides various products, which serves as predictive biomarkers and therapeutic targets for various human diseases and conditions, such as cancer, autoimmunity, diabetes, hypertension, obesity, inflammation, neurological disorders, and kidney failure. The Protein Platforms segment offers Biologics tools for researchers to interrogate protein purity and identify contaminants during the development and production of biologics; Western blot, an assay for protein analysis and identification; SimplePlex platform, an enzyme-linked immunosorbent assay for use in research and clinical diagnostics; and Single Cell Western platform to elucidate the properties of individual cells to understand cell behavior. The Diagnostics segment provides blood chemistry and gas quality controls, hematology instrument controls, diagnostic immunoassays, and other bulk and custom reagents for the in vitro diagnostic market. Bio-Techne Corporation has a strategic cooperation agreement with Micropoint Bioscience. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was founded in 1976 and is headquartered in Minneapolis, Minnesota.

Corporate Governance

Bio-Techne Corporation’s ISS Governance QualityScore as of November 1, 2018 is 1. The pillar scores are Audit: 5; Board: 2; Shareholder Rights: 1; Compensation: 3.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.